SCHEMBL4941492

SCHEMBL4941492

COc1ccc(-c2cccc(CC(=O)O)c2C)cc1

nearest known ligand 0.58

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MMP2 P08253 4/20 0.58
MMP12 P39900 4/20 0.58
MMP9 P14780 3/20 0.58
MMP8 P22894 3/20 0.53
MMP13 P45452 3/20 0.53
MMP14 P50281 3/20 0.53
MMP16 P51512 3/20 0.53
MMP1 P03956 1/20 0.53
MMP3 P08254 1/20 0.53
FFAR1 O14842 1/20 0.50
FFAR4 Q5NUL3 1/20 0.50
PTGS2 P35354 1/20 0.49
PTGS1 P23219 1/20 0.49
CD274 Q9NZQ7 3/20 0.49
PDCD1 Q15116 1/20 0.49
HSD17B10 Q99714 1/20 0.48
SUCNR1 Q9BXA5 1/20 0.47
PTGDR2 Q9Y5Y4 1/20 0.47
KDM4E B2RXH2 2/20 0.45
BACE1 P56817 1/20 0.45

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4216332 0.86 MMP2 (0.62) MMP2MMP12MMP9MMP8MMP13
SCHEMBL10713781 0.84 MMP2 (0.56) MMP2MMP12MMP9MMP8MMP13
SCHEMBL4941499 0.83 CD274 (0.53) PTGS2PTGS1CD274PDCD1SUCNR1
SCHEMBL13366126 0.83 CD274 (0.47) MMP2MMP12MMP9FFAR1FFAR4
SCHEMBL23512476 0.81 CD274 (0.50) FFAR1FFAR4PTGS2PTGS1CD274
SCHEMBL4945239 0.80 PREP (0.44) MMP2MMP12MMP9MMP8MMP13
SCHEMBL5266001 0.80 CYP11B1 (0.48) MMP2MMP12MMP9MMP8MMP13
SCHEMBL21738369 0.78 CD274 (0.46) FFAR1FFAR4CD274PDCD1BACE1
SCHEMBL25146592 0.77 PTGS2 (0.50) PTGS2PTGS1CD274PDCD1SUCNR1
SCHEMBL3738351 0.77 HSD17B10 (0.64) MMP2MMP12MMP9MMP8MMP13

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20080255111-A1 Tissue Factor Production Inhibitor SANKYO COMPANY LIMITED (JP) 2008-10-16 US disclosed
US-20080004301-A1 Benzene Compound Having 2 or More Substituents DAIICHI SANKYO COMPANY, LIMITED (JP) 2008-01-03 US disclosed
EP-1806332-A1 BENZENE COMPOUND HAVING 2 OR MORE SUBSTITUENTS Daiichi Sankyo Company, Limited (JP) 2007-07-11 EP disclosed
EP-1764075-A1 TISSUE FACTOR PRODUCTION INHIBITOR Sankyo Company, Limited (JP) 2007-03-21 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080255111-A1 Tissue Factor Production Inhibitor PTAFR, PLAT, TFPI MMP2 426/4885MMP12 67/4885MMP9 261/4885
US-20080004301-A1 Benzene Compound Having 2 or More Substituents NR1H2, NR1H3, NCOR2 MMP2 4839/4885MMP12 2945/4885MMP9 3071/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.